Physician profile
Benjamin L Rojas
NPI 1730320235
$15,617.76
in general payments reported to CMS, 2019-2025
54 companies · $1,541 in 2025
The $1,541 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,527 · 2020: $2,698 · 2021: $2,247 · 2022: $2,420 · 2023: $2,245 · 2024: $1,939 · 2025: $1,541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,625 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,625.43 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,645.44 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $1,628.08 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $1,383.93 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,271.35 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $978.13 | 2019-2025 | Jardiance |
| Amgen INC. | $903.68 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $863.57 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $677.28 | 2019-2025 | Wainua, Farxiga, Brilinta |
| Boston Scientific Corporation | $643.90 | 2019-2025 | Watchman Access System, Watchman Flx |
| Novo Nordisk INC | $546.03 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $398.31 | 2019-2025 | Cardiomems |
| Amarin Pharma, INC. | $392.45 | 2019-2022 | |
| Esperion Therapeutics, INC. | $386.36 | 2020-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $385.18 | 2021-2025 | Verquvo, Capvaxive |
| Lundbeck LLC | $380.24 | 2019-2021 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Rojas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.